S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?

NeuroSense Therapeutics (NRSN) News Today

$1.80
+0.41 (+29.50%)
(As of 02/27/2024 ET)
SourceHeadline
finance.yahoo.com logoNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
finance.yahoo.com - February 21 at 1:22 PM
prnewswire.com logoNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
prnewswire.com - February 21 at 8:30 AM
finance.yahoo.com logoNeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
finance.yahoo.com - February 7 at 1:25 PM
finanznachrichten.de logoNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
finanznachrichten.de - January 30 at 7:17 PM
finance.yahoo.com logoNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
finance.yahoo.com - January 30 at 8:44 AM
finance.yahoo.com logoNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
finance.yahoo.com - January 9 at 12:36 PM
finance.yahoo.com logoNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
finance.yahoo.com - January 4 at 1:25 AM
investing.com logoNeurosense Therapeutics (NRSN) Earnings Dates & Reports
investing.com - December 19 at 1:36 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)
markets.businessinsider.com - December 16 at 12:59 AM
finance.yahoo.com logoNeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
finance.yahoo.com - December 14 at 1:38 PM
markets.businessinsider.com logoAnalysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)
markets.businessinsider.com - December 8 at 4:27 AM
finance.yahoo.com logoWe're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
finance.yahoo.com - December 6 at 12:47 PM
marketwatch.com logoNeuroSense Therapeutics Sees Positive Safety Data in Phase 2 Trial for ALS Treatment, Shares Fall
marketwatch.com - December 5 at 9:47 AM
markets.businessinsider.com logoNeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary Endpoints
markets.businessinsider.com - December 5 at 9:47 AM
msn.com logoNeuroSense ALS candidate meets key study goals
msn.com - December 5 at 9:47 AM
finance.yahoo.com logoNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
finance.yahoo.com - December 5 at 9:47 AM
finance.yahoo.com logoNeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
finance.yahoo.com - December 4 at 5:58 PM
msn.com logoNeuroSense Therapeutics GAAP EPS of -$0.67
msn.com - November 28 at 12:46 PM
markets.businessinsider.com logoNeuroSense Therapeutics 9-Month Loss Narrows
markets.businessinsider.com - November 28 at 12:46 PM
finance.yahoo.com logoNeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - November 28 at 12:46 PM
markets.businessinsider.com logoNeuroSense Therapeutics Concludes Successful Type D Meeting With FDA For ALS Treatment
markets.businessinsider.com - November 13 at 3:05 PM
finance.yahoo.com logoNeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
finance.yahoo.com - November 13 at 10:04 AM
finance.yahoo.com logoNeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
finance.yahoo.com - November 6 at 8:38 AM
finance.yahoo.com logoNeuroSense Therapeutics to Participate in BIO-Europe Fall
finance.yahoo.com - November 1 at 10:23 AM
finance.yahoo.com logoRenowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
finance.yahoo.com - October 19 at 12:49 PM
marketbeat.com logo
marketbeat.com - October 19 at 10:45 AM
marketbeat.com logo
marketbeat.com - October 19 at 10:32 AM
finance.yahoo.com logoNeuroSense CEO Provides Q3 2023 Update
finance.yahoo.com - October 17 at 12:57 PM
finance.yahoo.com logoNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
finance.yahoo.com - October 4 at 10:12 AM
barrons.com logoNeuroSense Therapeutics Ltd. Wt
barrons.com - September 25 at 8:46 PM
finance.yahoo.com logoEuropean Medicines Agency Grants NeuroSense SME Status
finance.yahoo.com - September 20 at 1:34 PM
finance.yahoo.com logoNeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
finance.yahoo.com - September 19 at 10:37 AM
finance.yahoo.com logoNeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
finance.yahoo.com - September 14 at 11:19 AM
finance.yahoo.com logoNeuroSense to Host Investor Webinar on September 12, 2023
finance.yahoo.com - September 6 at 9:25 AM
finance.yahoo.com logoNeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - August 16 at 9:32 AM
finance.yahoo.com logoNeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
finance.yahoo.com - July 17 at 9:42 AM
finance.yahoo.com logoNeuroSense CEO Provides Q2 2023 Update
finance.yahoo.com - July 6 at 1:04 PM
finance.yahoo.com logoNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
finance.yahoo.com - June 22 at 9:55 AM
markets.businessinsider.com logoMaxim Group Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)
markets.businessinsider.com - June 14 at 5:56 PM
markets.businessinsider.com logoNeurosense Therapeutics Ltd. (NRSN) Gets a Buy from Maxim Group
markets.businessinsider.com - June 3 at 3:36 PM
benzinga.com logoNeuroSense Therapeutics Q1 EPS $(0.33) Down From $(0.24) YoY
benzinga.com - June 2 at 7:33 PM
finance.yahoo.com logoNeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
finance.yahoo.com - June 1 at 1:20 PM
finance.yahoo.com logoNeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
finance.yahoo.com - May 15 at 10:04 AM
markets.businessinsider.com logoNeuroSense Reports Positive Preliminary Results From Parkinson's Disease Biomarker Study
markets.businessinsider.com - May 2 at 2:07 PM
finance.yahoo.com logoNeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study
finance.yahoo.com - May 2 at 9:06 AM
seekingalpha.com logoNRSN NeuroSense Therapeutics Ltd.
seekingalpha.com - April 29 at 7:28 PM
finance.yahoo.com logoNeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
finance.yahoo.com - April 17 at 9:59 AM
finance.yahoo.com logoNeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
finance.yahoo.com - March 27 at 12:27 PM
markets.businessinsider.com logoMaxim Group Reaffirms Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)
markets.businessinsider.com - March 25 at 7:04 PM
finance.yahoo.com logoNeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
finance.yahoo.com - March 23 at 1:59 PM
Get NeuroSense Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.



NRSN Media Mentions By Week

NRSN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NRSN
News Sentiment

0.70

0.51

Average
Medical
News Sentiment

NRSN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NRSN Articles
This Week

3

1

NRSN Articles
Average Week

Get NeuroSense Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:NRSN) was last updated on 2/28/2024 by MarketBeat.com Staff